Key result
Mendelian randomization studies on hyperuricemia and gout show highly variable quality without improvement over time.
Why the study?
The quality of two-sample Mendelian randomization studies on hyperuricemia and gout varies and requires systematic evaluation to ensure validity and robustness.
Systematic Review (n=86)
A proposed scoring system offers a practical framework for evaluating the quality of Mendelian randomization studies, which currently show significant variability and lack of improvement over time.
Many two-sample MR studies in gout show poor quality; challenges reliability of causal claims and demands stricter methodological standards.
Background: Mendelian randomization (MR) is a genetic epidemiological method used to infer causal relationships between exposures and outcomes. Its application in hyperuricemia and gout has grown exponentially owing to the ready availability of summary statistics from genome-wide association studies and the ease of applying the two-sample MR technique. However, indications of poor study quality suggest the need for systematic evaluation. Objective: This study evaluated the quality of two-sample MR studies on hyperuricemia and gout and developed a scoring system to help reviewers and readers assess their quality and validity. Methods: A systematic review was conducted on 86 two-sample MR studies published between 2016 and 2024. Studies were assessed using a scoring system encompassing study design, statistical methods, result interpretation, and adherence to STROBE-MR guidelines. Scores could range between -9 and 21. Trends in quality over time were analyzed using regression models. Results: -value when needed, test for confounders, address dataset overlap, or report study power. Despite the increased publication of MR studies, overall quality has not improved over time. Conclusion: There is variability in two-sample MR study quality. Our proposed scoring system offers a practical framework for evaluating MR studies, aiding researchers and clinicians in identifying robust findings while promoting higher methodological standards.
No takes yet. Share an insight, caveat, or question.
Rosas-Chavez et al. (2025) conducted a systematic review in Hyperuricemia and gout (n=86). Two-sample Mendelian randomization studies was evaluated on Study quality assessed using a scoring system (range -9 to 21). A systematic review of 86 two-sample Mendelian randomization studies on hyperuricemia and gout found significant variability in study quality, which has not improved over time.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: